title: 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri.
abstract: OBJECTIVE
  The goal of this study was to evaluate the effects of single fractions of 10 Gy pelvic irradiation for palliation and life prolongation in patients with cancer of the uterine cervix or corpus.
  
  
  METHODS
  A retrospective analysis was performed on 37 cervical cancer and 27 corpus cancer patients treated in the period 1988-1998. All patients had a life expectancy of less than 1 year. Due to stage of disease, age (median 82 years), or comorbidity they were considered unapt for surgery or conventional radiotherapy. Eleven patients with recurrence within irradiated field or early progression received one, 51 patients received two, and 2 patients received three fractions with a 4-week interval.
  
  
  RESULTS
  Vaginal bleeding stopped in 90% and malodorous discharge in 39% of the patients. Among 46 patients with advanced disease treated for palliation, 10 (22%) showed complete tumor responses. Median time to progression was 6 months, and median survival, 9 months. Eighteen patients with early-stage disease and serious comorbidity were treated with life prolongation and symptom prevention as intention, and showed seven complete responses. Median survival was 13 months, and half the deaths were caused by intercurrent disease. Median hospital stay was 5 days and rehabilitation was easy. Fifty-six percent of the patients experienced no acute side effects and 33% had minor gastrointestinal problems. Three patients (6%) had serious late bowel complications, one with a fatal outcome, the symptoms appearing 9-10 months posttreatment.
  
  
  CONCLUSIONS
  The 10-Gy single-fraction pelvic radiation regimen is an effective means of symptom palliation and is well tolerated. Tumor responses are obtained. The risk of late bowel complications is a concern for patients with a life expectancy greater than 9 months.
authors: Department of Gynecologic Oncology, University Hospital, Trondheim, 7006, Norway. mathiaso@frisurf.no
authors: M
authors: M
authors: Onsrud
authors: B
authors: B
authors: Hagen
authors: T
authors: T
authors: Strickert
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000401:mortality / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008020:Life Support Care / Q000379:methods*; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods*; D010388:Pelvis / Q000528:radiation effects*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000401:mortality / Q000532:radiotherapy*; D014594:Uterine Neoplasms / Q000150:complications / Q000401:mortality / Q000532:radiotherapy*